Gilead reports modest sales rise but analysts question future growth beyond HIV drugs
Gilead's second‑quarter results showed total product revenue of $7.6 billion, up 8% year‑over‑year.
The company's two leading HIV treatments, Biktarvy and Descovy, together generated about $5.7 billion, exceeding analysts’ expectations.
A newer therapy, Yeztugo, posted sales of $232 million, matching forecasts and keeping it on track for the company’s $1 billion target for the year.
Despite the earnings beat, investors remain uneasy because HIV products still dominate Gilead’s portfolio, and the firm has revised its outlook for overall HIV sales to 9‑10% growth in 2026, up from the prior 8% estimate.
The mixed signals highlight the challenge Gilead faces in diversifying beyond its core HIV franchise while maintaining investor confidence.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that